FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030219408> ?p ?o ?g. }

• W2030219408 endingPage "711" @default.
• W2030219408 startingPage "701" @default.
• W2030219408 abstract "We have reported previously that thromboxane A2 (TXA2) and serotonin (5-HT, 5-hydroxytryptamine) are important mediators of cyclic flow variations (CFVs) in a canine model of coronary artery stenosis and endothelial injury. The present study tested the hypothesis that a TXA2 receptor antagonist is more effective in reducing intracoronary platelet deposition at sites of endothelial injury and severe stenosis than a 5-HT2 receptor antagonist. CFVs developed after placing a plastic constrictor around the left anterior descending coronary artery (LAD) in 51 of 56 dogs. Autologous platelets labeled with 111In were injected in 48 animals. Ten control dogs (group 1A) were killed after CFVs were observed for 1 hour at the nadir of coronary blood flow. Five dogs (group 1B) did not develop CFVs after placement of the constrictor. CFVs were abolished with SQ 28668 (2.75 +/- 0.36 mg/kg, group 2) and SQ 29548 (0.45 +/- 0.1 mg/kg, group 3), two different TXA2 and PGH2 receptor antagonists, in eight of 10 and six of seven dogs, respectively. In eight of 10 dogs (group 4), CFVs were abolished with ketanserin (0.66 +/- 0.12 mg/kg), a 5-HT2 receptor antagonist. In group 2, 3, and 4 dogs, the respective drugs were given so that the minimal dose required to abolished CFVs was administered. In six of six dogs (group 5), a higher dose of ketanserin (i.e., 1.5 mg/kg) was used to abolish CFVs. At death, intracoronary platelet deposition was evaluated by calculating the LAD platelet accumulation ratio (111In activity in the LAD/111In activity in the circumflex coronary artery) in 43 dogs and, in 22 dogs, by microscopic examination of the LAD. A marked LAD platelet accumulation ratio was found in group 1A dogs at the stenotic site and in segments immediately distal to it. The LAD platelet accumulation ratio was significantly reduced by both the low and the high doses of ketanserin compared with group 1A dogs (p less than 0.001). However, the two TXA2 receptor antagonists further reduced the LAD platelet accumulation ratio compared with ketanserin-treated animals (p less than 0.01). Microscopic examination confirmed these findings. We conclude that SQ 28668 and SQ 29548, two different TXA2 receptor antagonists, reduce residual intracoronary platelet deposition associated with CFVs in this canine model more effectively than ketanserin, a 5-HT2 receptor antagonist." @default.
• W2030219408 created "2016-06-24" @default.
• W2030219408 creator A5001301886 @default.
• W2030219408 creator A5034394063 @default.
• W2030219408 creator A5038526875 @default.
• W2030219408 creator A5045515686 @default.
• W2030219408 creator A5076130506 @default.
• W2030219408 creator A5085845770 @default.
• W2030219408 date "1988-09-01" @default.
• W2030219408 modified "2023-09-25" @default.
• W2030219408 title "Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries." @default.
• W2030219408 cites W1966409965 @default.
• W2030219408 cites W1967189169 @default.
• W2030219408 cites W1971356555 @default.
• W2030219408 cites W1984061640 @default.
• W2030219408 cites W1984323352 @default.
• W2030219408 cites W1988733687 @default.
• W2030219408 cites W1996350892 @default.
• W2030219408 cites W2012214760 @default.
• W2030219408 cites W2021365318 @default.
• W2030219408 cites W2024960804 @default.
• W2030219408 cites W2030087792 @default.
• W2030219408 cites W2030756815 @default.
• W2030219408 cites W2055642132 @default.
• W2030219408 cites W2058329709 @default.
• W2030219408 cites W2061755142 @default.
• W2030219408 cites W2065804664 @default.
• W2030219408 cites W2065993385 @default.
• W2030219408 cites W2071485229 @default.
• W2030219408 cites W2079184391 @default.
• W2030219408 cites W2153530728 @default.
• W2030219408 cites W2313425863 @default.
• W2030219408 cites W2316166446 @default.
• W2030219408 cites W2340410345 @default.
• W2030219408 cites W4297820806 @default.
• W2030219408 doi "https://doi.org/10.1161/01.cir.78.3.701" @default.
• W2030219408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3409505" @default.
• W2030219408 hasPublicationYear "1988" @default.
• W2030219408 type Work @default.
• W2030219408 sameAs 2030219408 @default.
• W2030219408 citedByCount "73" @default.
• W2030219408 countsByYear W20302194082012 @default.
• W2030219408 countsByYear W20302194082017 @default.
• W2030219408 crossrefType "journal-article" @default.
• W2030219408 hasAuthorship W2030219408A5001301886 @default.
• W2030219408 hasAuthorship W2030219408A5034394063 @default.
• W2030219408 hasAuthorship W2030219408A5038526875 @default.
• W2030219408 hasAuthorship W2030219408A5045515686 @default.
• W2030219408 hasAuthorship W2030219408A5076130506 @default.
• W2030219408 hasAuthorship W2030219408A5085845770 @default.
• W2030219408 hasBestOaLocation W20302194081 @default.
• W2030219408 hasConcept C126322002 @default.
• W2030219408 hasConcept C164705383 @default.
• W2030219408 hasConcept C170493617 @default.
• W2030219408 hasConcept C2775864247 @default.
• W2030219408 hasConcept C2776785769 @default.
• W2030219408 hasConcept C2776820930 @default.
• W2030219408 hasConcept C2776885963 @default.
• W2030219408 hasConcept C2777785214 @default.
• W2030219408 hasConcept C2778122271 @default.
• W2030219408 hasConcept C2778742706 @default.
• W2030219408 hasConcept C2781024287 @default.
• W2030219408 hasConcept C3018697912 @default.
• W2030219408 hasConcept C42219234 @default.
• W2030219408 hasConcept C53910766 @default.
• W2030219408 hasConcept C71924100 @default.
• W2030219408 hasConcept C89560881 @default.
• W2030219408 hasConceptScore W2030219408C126322002 @default.
• W2030219408 hasConceptScore W2030219408C164705383 @default.
• W2030219408 hasConceptScore W2030219408C170493617 @default.
• W2030219408 hasConceptScore W2030219408C2775864247 @default.
• W2030219408 hasConceptScore W2030219408C2776785769 @default.
• W2030219408 hasConceptScore W2030219408C2776820930 @default.
• W2030219408 hasConceptScore W2030219408C2776885963 @default.
• W2030219408 hasConceptScore W2030219408C2777785214 @default.
• W2030219408 hasConceptScore W2030219408C2778122271 @default.
• W2030219408 hasConceptScore W2030219408C2778742706 @default.
• W2030219408 hasConceptScore W2030219408C2781024287 @default.
• W2030219408 hasConceptScore W2030219408C3018697912 @default.
• W2030219408 hasConceptScore W2030219408C42219234 @default.
• W2030219408 hasConceptScore W2030219408C53910766 @default.
• W2030219408 hasConceptScore W2030219408C71924100 @default.
• W2030219408 hasConceptScore W2030219408C89560881 @default.
• W2030219408 hasIssue "3" @default.
• W2030219408 hasLocation W20302194081 @default.
• W2030219408 hasLocation W20302194082 @default.
• W2030219408 hasOpenAccess W2030219408 @default.
• W2030219408 hasPrimaryLocation W20302194081 @default.
• W2030219408 hasRelatedWork W153275167 @default.
• W2030219408 hasRelatedWork W1986728065 @default.
• W2030219408 hasRelatedWork W2012241915 @default.
• W2030219408 hasRelatedWork W2013988676 @default.
• W2030219408 hasRelatedWork W2017328565 @default.
• W2030219408 hasRelatedWork W2058306971 @default.
• W2030219408 hasRelatedWork W2077019782 @default.
• W2030219408 hasRelatedWork W2093519666 @default.
• W2030219408 hasRelatedWork W2566617483 @default.
• W2030219408 hasRelatedWork W2980115092 @default.

• next